


GHG 18 (Saxon Clinic) Limited

Report and Financial Statements

for the period ended 18 April 2017



Company Number: 05783495

GHG 18 (Saxon Clinic) Limited

Report and financial statements for the period ended 18 April 2017

Contents page:

1	Company directory
2 - 4	Strategic report
5	Report of the Director
6	Statement of Director's responsibilities
7 - 8	Independent auditors report
9	Income statement
10	Statement of financial position
11	Statement of changes in equity
12	Definitions
13 - 25	Notes forming part of the financial statements

GHG 18 (Saxon Clinic) Limited

Company Directory

Director

D Duggins

Registered Office

GHG 18 (Saxon Clinic) Limited
c/o Maitland Administration Services (Scotland) Ltd
(formerly R&H Fund Services Limited)
8th Floor
6 New Street Square
New Fetter Lane
London
EC4A 3AQ

Company Incorporated and Registered in United Kingdom

Company Secretary

Maitland Administration Services (Scotland) Ltd
(formerly R&H Fund Services Limited)
8th Floor
6 New Street Square
New Fetter Lane
London
EC4A 3AQ

Legal Advisors

Milbank, Tweed, Hadley & McCloy LLP
10 Gresham Street
London
EC2V 7JD

Independent Auditors

BDO LLP
55 Baker Street
London
W1U 7EU

GHG 18 (Saxon Clinic) Limited

Strategic Report

The Director, in preparing this strategic report, has complied with s414C of the Companies Act 2006.

Background

The Company is one of 36 companies which were formed in 2006. One of the companies acts as cash collection and disbursement agent for the others, each of which acquired a single UK private hospital property which were simultaneously all leased to a single tenant on long term leases expiring in 2031, with the tenant having the right to extend for a further ten years. Collectively, those companies which own a property are hereinafter referred to as the "Theatre Propcos" and each a "Theatre Propco".

Debt funding for the acquisition of the properties was provided to the Theatre Propcos under a single set of finance agreements by multiple banks on a medium term basis, with final repayment due in October 2013. Each Theatre Propco, including the Company, received an allocated amount of the debt and became and continues to be a joint guarantor under those financing arrangements; the assets of each Theatre Propco being pledged to guarantee and secure the entire debt which was £1.65 billion at the outset, together with related interest rate swaps. The finance agreement was subsequently renewed and maturity was extended to 15 April 2019.

Ownership

Throughout the period, the Company was a wholly-owned subsidiary of Hospital Midco S.a.r.l, a company incorporated in Luxembourg. The ultimate parent and controlling party throughout the period was Hospital Topco Limited, a company incorporated in the United Kingdom.

Business review

The Company owns a single UK private hospital/healthcare property (The Saxon Clinic), which is occupied and operated by a single tenant (which is also the sole tenant of all the properties owned by the Theatre Propcos) on a long term lease, with the tenant being responsible for the insurance of, repairs to and maintenance of the property. The rent under the lease is increased annually by reference to changes in the UK Retail Prices Index ("RPI"). The tenant is solely responsible for the operation of the private hospital/healthcare facility, including compliance with applicable health and safety legislation as it relates to the property.

The Company's business is therefore one of an investment property company. The Company's only source of income is the rent from the property, which is received quarterly in advance and paid directly to an agent company as described in the financial statements. Those funds are used to pay interest on, and the quarterly repayments of the Company's bank debt and interest rate swap costs, together with lenders' fees and certain administrative costs. For each Theatre Propco, any surplus funds each quarter are swept by the lenders to further repay that company's debt facility and/or the bank debt of other Theatre Propcos of which the Company is a joint guarantor. Conversely, if a Theatre Propco's income is insufficient to meet its mandatory debt repayment, interest and swap costs, it is made good by other Theatre Propcos which have surpluses.

The valuation of the Company's properties decreased during the period as a result of the underlying performance of the hospitals, and the general property market conditions within the healthcare sector.

The Company has no cash and no bank account; all its cash receipts and payments being administered by GHG 38 (Property Holdings) Limited which acts as cash collection and disbursement agent for all the Theatre Propcos. The Company has no permanent staff and relies on outsourced services.

Company objectives

The Company's objectives are to manage its property, collect the rent due and service and gradually pay down the Company's debt.

GHG 18 (Saxon Clinic) Limited

Strategic Report (continued)

Results and dividends

2017 results

As will be seen in the Income Statement within the attached financial statements, the Company made a profit before taxation for the period of £0.296 million (15 April 2016: £0.161 million profit). The Director is unable to recommend the payment of a dividend (15 April 2016: £Nil) as the Company does not have distributable reserves.

Principal risks and uncertainties

The Company is exposed to financial risk through its assets and liabilities. The most important components of financial risk are interest rate risk, currency risk, liquidity risk, credit risk and price risk.

Due to the nature of the Company's business and the assets and liabilities contained within the Company's Statement of Financial Position, the Director considers that all financial risks except currency risk are relevant to the Company.

Interest rates risk

The only significant assets and liabilities of the Company that are interest bearing are its obligations to its lenders. The interest rate on that debt was established in 2006 on a floating rate basis. However, to protect the Company from unexpected rises in interest rates, interest rate swap agreements were put in place to cover the period until the expiry of the existing lease on the Company's property in 2031. These swap arrangements were subsequently cancelled and replaced with new swap arrangements which extend to 2021. Details of these arrangements, which convert the Company's floating rate exposure to known fixed rates, are set out within Note 14 to the financial statements. The Company does not speculate in the trading of derivative instruments.

Liquidity risk

The Company's income is contractually determined within a long term lease of its property and, subject to an annual operating budget, its bank lenders are entitled to sweep the entirety of that income towards repayment and servicing of the bank debt and the interest rate swap costs. The Company (in common with the other Theatre Propcos) has a committed debt facility which matures in April 2019.

The continued availability of finance to the Company will depend upon its ability to meet loan covenants in the future.

GHG 18 (Saxon Clinic) Limited

Strategic Report (continued)

Credit risk

The Company has one property that is occupied by a single tenant. The Company therefore monitors the financial position of its tenant. The rent is indexed upwards annually. In addition, the tenant owes the Company and other Theatre Propcos deferred rent totalling some £28 million in respect of the initial quarter's rent in 2006, which both parties agreed to defer at the outset of the property leases in 2006.

On the basis of publicly available information, the Director believes that the tenant is capable of continuing to pay the rent in the short term and settling the deferred rent when it becomes due. In the longer term, the tenant's ability to meet the increasing rent and all other required expenditures will be dependent on its ability to grow its business profitably.

Also, there is an indemnity agreement between the Company, the other Theatre Propcos and the tenant, which may give rise to other material obligations on the tenant.

Price risk

The terms of the lease over the property between the Company and the tenant are established within a long term lease which runs to 2031, with a tenant option to extend for a further ten years. The lease requires the rent to be increased (but not reduced) each year by reference to the United Kingdom Index of Retail Prices, subject to a cap of 4% pa. The Company also has RPI swap arrangements which have the effect of adjusting the annual rent increase to 2.5%. Other than through future changes to the lease arrangements, the Company is not able to manage price risk until the maturity of the current lease.


Property Valuation Risk

As noted on page 2, the valuation of the properties reflects the underlying performance of the hospitals, and the general property market conditions within the healthcare sector.

Going concern

The Director has concluded that it is appropriate to prepare the financial statements on the going concern basis and therefore presents the financial statements accordingly.

This report was approved by the Director and signed on 2 August 2017.


.....
D Duggins
Director

GHG 18 (Saxon Clinic) Limited

Report of the Director

The Director has pleasure in presenting this report and the financial statements of GHG 18 (Saxon Clinic) Limited ("the Company") for the period 16 April 2016 to 18 April 2017. Certain matters have been dealt with in the Strategic Report and are not repeated here.

Incorporation

The Company was incorporated on 18 April 2006 in the United Kingdom. The Company's name on incorporation was Pantomime Propco 18 Limited and it was changed to GHG 18 (Saxon Clinic) Limited on 7 November 2006.

Principal activity

The principal activity of the Company is to hold investment property located in the United Kingdom.

Director

The Director holding office during the period and through to the date of signing of this report are:

D Duggins

Directors' and officers' insurance


The Company has director's and officers' insurance for the benefit of, amongst others, the Director of the Company, which is in place at the date of this report.

Independent auditor

The auditors, BDO LLP have expressed their willingness to continue in office.

So far as the Director is aware, there is no relevant audit information of which the Company's auditor is unaware, and the Director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This report was approved by the Director and signed on 2 August 2017.


.....
D Duggins
Director

GHG 18 (Saxon Clinic) Limited

Statement of Director's Responsibilities

The Director is responsible for preparing the Strategic report and the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the Director to prepare financial statements for each financial year. Under that law the Director has prepared the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including the Financial Reporting Standard 102 The Financial Reporting Standard Applicable in the UK and Republic of Ireland (FRS 102).

Under company law the Director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of the Company and its profit or loss for that period. In preparing these financial statements, the Director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue the business; and
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements.

The Director confirms they have complied with all the above requirements in preparing the financial statements.

The Director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.

GHG 18 (Saxon Clinic) Limited

Independent Auditors Report

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF GHG 18 (SAXON CLINIC) LIMITED

We have audited the financial statements of GHG 18 (Saxon Clinic) Limited for the period ended 18 April 2017 which comprise the income statement, the statement of financial position, the statement of changes in equity and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the statement of director's responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Financial Reporting Council's (FRC's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the FRC's website at www.frc.org.uk/auditscopeukprivate.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the Company's affairs as at 18 April 2017 and of its profit for the period then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the case of the audit :

- the information given in the strategic report and the directors' report for the financial period for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and directors' report have been prepared in accordance with the applicable legal requirements.

GHG 18 (Saxon Clinic) Limited
Independent Auditors Report (*continued*)

Matters on which we are required to report by exception

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

BDO LLP

Charles Ellis (Senior statutory auditor)
For and on behalf of BDO LLP, Statutory auditor
London
United Kingdom

Date: *4 August 2017*

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

GHG 18 (Saxon Clinic) Limited

Income Statement for the period ended 18 April 2017

	Note	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
Turnover	5	2,673	2,341
Administrative expense	6	(535)	(223)
Gain on revaluation of RPI swap	6	533	274
Loss from changes in fair value of investment property	9	(647)	(266)
Profit on ordinary activities before interest and tax		2,024	2,126
Loss on revaluation of interest rate swap	6	(299)	(687)
Interest payable and similar charges	7	(1,429)	(1,278)
Operating profit		296	161
Tax on ordinary activities	8	81	(169)
Profit / (loss) for the financial period		377	(8)
Other comprehensive income / (loss)		-	-
Total comprehensive income / (loss) for the period		377	(8)

All operations are considered to be continuing.


The notes on pages 13 to 25 form part of these financial statements.

GHG 18 (Saxon Clinic) Limited

Statement of Financial Position at 18 April 2017

	Note	18 April 2017 £000	15 April 2016 £000
Fixed assets			
Tangible assets	9	32,335	32,982
Current assets			
Debtors: due within one year	10	540	540
Debtors: due more than one year	11	1,050	598
		<u>1,590</u>	<u>1,138</u>
Creditors: amount falling due within one year	12	<u>(1,977)</u>	<u>(1,661)</u>
Net current liabilities		(387)	(523)
Total assets less current liabilities		<u>31,948</u>	<u>32,459</u>
Creditors: amount falling due after more than one year	13	(34,154)	(34,962)
Provisions for liabilities	15	(3,195)	(3,275)
Net liabilities		<u><u>(5,401)</u></u>	<u><u>(5,778)</u></u>
Capital and reserves			
Called up share capital	18	-	-
Share premium account	19	-	-
Profit and loss account	19	(5,401)	(5,778)
Total deficit		<u><u>(5,401)</u></u>	<u><u>(5,778)</u></u>

The financial statements for GHG 18 (Saxon Clinic) Limited, registered number 05783495 were approved by the Director and authorised for issue on 2 August 2017.



D Duggins
 Director

The notes on pages 13 to 25 form part of these financial statements.

GHG 18 (Saxon Clinic) Limited

Statements of Changes in Equity for the period ended 18 April 2017

	Share Capital £000	Share Premium £000	Profit and Loss Account £000	Total Equity £000
28 May 2015	-	5,037	(11,171)	(6,134)
Total comprehensive loss for the period	-	-	(8)	(8)
<u>Contributions by and distributions to owners</u>				
Capital contribution	-	-	364	364
Capital reduction	-	(5,037)	5,037	-
15 April 2016	-	-	(5,778)	(5,778)
Total comprehensive income for the period	-	-	377	377
18 April 2017	-	-	(5,401)	(5,401)

The notes on pages 13 to 25 form part of these financial statements.

GHG 18 (Saxon Clinic) Limited

Definitions for the period ended 18 April 2017

Due to the complexity and inter-related nature of a number of matters set out within these financial statements, to eliminate the need for repeated descriptions, the following defined terms are used throughout the financial statements:

"Deferred Rent Agreement" means the agreement entered into in 2006 between the Theatre Propcos and the Tenant under which it was mutually agreed that the Tenant deferred payment of the first quarter's rent under its leases with the Theatre Propcos.

"Interest Rate Swaps" mean the arrangements described in more detail in Note 17 to the financial statements under which the Theatre Propcos pay interest on the Theatre Propcos' Debt at a fixed rate of interest rather than the floating rate that was originally specified by the Lenders;

"Lenders" means the various banks and other financial institutions which provided and continue to provide the Theatre Propcos' Debt, including at any time new lenders that have subsequently bought such debt from the original issuers;

"Senior Debt" means that tranche of the Company's debt facilities which ranks ahead of other tranches for repayment in the event that the Lenders' security is enforced.

"Tax & Expenses Indemnity" means the agreement entered into in 2006 between the Theatre Propcos, the Tenant and others under which the Tenant is required to settle (without being entitled to reimbursement by the relevant Theatre Propco) any costs, fees and expenses required to maintain each Theatre Propco's corporate existence and any administrative costs, directors' fees, professional fees and regulatory costs incurred in the ordinary course of each Theatre Propco's business and, under certain circumstances, liabilities to taxation for which each Theatre Propco becomes liable.

"Tenant" means BMI Healthcare Limited, which is the sole lessee of all properties owned by the Theatre Propcos;

"Theatre Propcos" means the Company and 34 other UK companies which are each joint guarantors of the Theatre Propcos' Debt and a further company which acts as agent; each Theatre Propco owning a UK hospital property, the acquisition of which was partly financed by the Theatre Propcos' Debt and which properties are leased to and operated by the Tenant and **"Theatre Propco"** means any one of the Theatre Propcos; and

"Theatre Propcos' Debt" means the amount outstanding at any time of the loan facility of £1.65 billion advanced by the Lenders and drawn in full by the Theatre Propcos in 2006 (of which the Company's bank debt forms a part) and which is secured upon all the assets and shares of the Theatre Propcos and their Immediate Holding Company.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017

1 Company Information

Date of Incorporation

The Company was incorporated in the United Kingdom under the Companies Act 2006 on 18 April 2006.

Principal activity

The principal activity of the Company is to hold investment property located in the United Kingdom.

Registered office

The registered office of the Company is c/o Maitland Administration Services (Scotland) Ltd (formerly R&H Fund Services Limited, 8th Floor, 6 New Street Square, New Fetter Lane, London. EC4A 3AQ.

2 Principal accounting policies

The principal accounting policies are summarised below, which have all been applied consistently throughout the period and prior period, except where stated otherwise.

Basis of preparation

The financial statements have been prepared in accordance with applicable United Kingdom accounting standards, including Financial Reporting Standard 102 – The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and with The Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 4).

The financial statements have been presented in Pounds Sterling (£) rounded to the nearest thousand, this is the functional currency of the Company.

Going concern

The financial statements are prepared on the going concern basis unless it is inappropriate to assume that the Company will be able to continue in operational existence for a period of at least 12 months from the date of approval of the financial statements.

Note 3 to the financial statements sets out the matters considered by the Director in arriving at the conclusion that it is appropriate to prepare these financial statements on the going concern basis.

Investment properties

Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.

Financial assets

Basic financial assets, including trade and other receivables, are initially recognised at transaction price.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (continued)

2 Principal accounting policies (continued)

Financial assets (continued)

If there is decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities

Basic financial liabilities, including trade and other payables, loans, are initially recognised at transaction price.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Borrowing costs

Borrowing costs incurred, are deducted from the initial carrying value of loans and are charged to profit or loss as part of the interest charge calculated using the straight line method over the length of the loan.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value using a pre-tax discount rate. The unwinding of the discount is recognised as a finance cost in the profit and loss account in the year it arises.

Cash flow statement

The Company does not have a bank account. The rental income receivable by the Company from the Tenant is paid to GHG 38 (Property Holdings) Limited ("GHG 38"), which acts as cash collection and disbursement agent for all the Theatre Propcos, and is distributed from there principally to the Lenders and Interest Rate Swap counterparties in accordance with the overall finance documents. GHG 38's bank accounts are operated by the Lenders' Facility Agent in accordance with the Lenders' instructions. In view of these contractual arrangements, the Company is not required to present a cash flow statement.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (*continued*)

2 Principal accounting policies (continued)

Derivative financial instruments

The Company has entered into derivative financial instruments to eliminate exposure to interest rate movements, and to adjust the variable annual rent increases under its property lease to a fixed annual increase. The Company does not hold or issue derivative financial instruments for speculative purposes.

These financial instruments are carried at fair value, based on expected future cash flows adjusted for any credit risk associated with the contractual counterparty. Movements in fair value are recognised in profit and loss.

Share capital and share premium

Called up share capital is determined using the nominal value of share that have been issued. Share premium includes any premium received on the initial issuing of the share capital

Turnover

Company turnover comprises rental income receivable from operating leases in the normal course of the business net of all refunds, allowances and value added tax. Rental income recognition is based on an accruals basis.

Taxation

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates taxable income.

Deferred balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits;
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met; and
- Where timing differences relate to interests in subsidiaries, associates, branches and joint ventures and the group can control their reversal and such reversal is not considered probable in the foreseeable future.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax.

Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

Related parties

The Company discloses transactions with related parties. It does not disclose transactions with members of the same group that are wholly owned.

Expenses

Expenses are accounted for on an accruals basis.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (*continued*)

3 Going concern

In determining whether there is a reasonable prospect of the Company continuing in business as a going concern, the key matter that must be considered is the debt due to the Lenders. The Director considers that the Company will be able to comply with all the requirements of the debt facility until maturity in April 2019. The Director believes the facility will be renewed, replaced or renegotiated on or before 15 April 2019 and has therefore concluded that it is appropriate to prepare the financial statements on a going concern basis and presents the financial statements accordingly.

4 Judgements in applying accounting policies and key sources of estimation uncertainty

In preparing these financial statements estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

- Determine whether closing debtor balances are deemed fully collectable. This action requires a review of debt balances and the economic viability of tenants owing monies, using judgement to estimate the amount of impairment loss to recognise through the income statement.

Other key sources of estimation uncertainty

- *Investment property (see note 9)*

Investment properties are professionally valued annually using a yield methodology which have been based on comparable transactional evidence in the market place together with the assessment of the quality and length of the income stream, current rental values, capitalised at a market rate, but there is an inevitable degree of judgement involved, as each property is unique and value can only be reliably tested in the market itself.

- *Interest rate derivatives (see note 17)*

The most critical estimates, assumptions and judgements relate to the determination of carrying value of swaps at fair value through the income statement. In determining this, the Group uses a third party valuation, applying the concept that fair value is the amount for which the derivative could be traded. There are judgements based on the future rates of interest which affect the valuation.

- *RPI linked derivatives (see note 17)*

The most critical estimates, assumptions and judgements relate to the determination of carrying value of swaps at fair value through the income statement. In determining this, the Company uses a third party valuation, applying the concept that fair value is the amount for which the derivative could be traded. There are judgements based on the future rates of inflation which affect the valuation.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (*continued*)

5 Analysis of turnover

	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
Rental income	2,673	2,341
	<u>2,673</u>	<u>2,341</u>

All turnover within the Company has arisen within the United Kingdom, where the investment property is situated.

The future aggregate minimum rentals receivable under non-cancellable operating leases are as follows:

	2017 £000	2016 £000
Future rentals under operating leases		
No later than one year	2,665	2,643
Later than one year and no later than five years	10,660	10,571
Later than 5 years	25,432	27,860
	<u>38,757</u>	<u>41,074</u>

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (*continued*)

6 Operating profit

	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
Audit fees	2	2
Gain on revaluation of RPI swap	(533)	(274)
Other expenses	103	73
Intercompany provision movement	430	148
	<u>2</u>	<u>(51)</u>
Loss on revaluation of interest rate swap	299	687
Interest payable and similar charges	1,429	1,278
Total expenses on ordinary activities before taxation	<u><u>1,730</u></u>	<u><u>1,914</u></u>

There were no employees of the Company in either period.

The Director received remuneration for his activities as a director of all the Theatre Propcos. The Company's share of that remuneration during the period was £4,626 (2016: £3,142).

The audit fee for the audit of the Company's annual accounts was £2,491 (2016: £1,500). The auditor received no non audit fees during the period (2016: £Nil).

7 Interest payable

	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
On bank loans	1,404	1,252
Debt service costs	25	26
	<u><u>1,429</u></u>	<u><u>1,278</u></u>

The Company continues to pay the fixed rate of interest specified in the Interest Rate Swap agreements. The floating rate of interest has been charged to the current period's income statement.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (*continued*)

8 Tax on profit on ordinary activities

	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
Corporation tax	-	-
Deferred tax (see Note 16) (Credit) / charge to the profit and loss account	(81)	169
Tax on ordinary activities	<u>(81)</u>	<u>169</u>

Factors affecting tax charge for the period

The difference between the corporation tax shown above and the amounts calculated by applying the standard rate of corporation tax to the profit before tax is as follows:

	Period 16.04.16 - 18.04.17 £000	Period 29.05.15 - 15.04.16 £000
<u>UK corporation tax</u>		
Profit on ordinary activities before tax	<u>296</u>	<u>161</u>
Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 19.84% (April 2016: 20%)	59	32
Effects of:		
Impact of change in tax rates	(163)	(105)
Adjustment to carried forward loss for prior year	(18)	(17)
Other	41	259
Total	<u>(81)</u>	<u>169</u>

The Director estimates that the Company has tax losses available for offset against future taxable profits of £4.165 million (2016: £5.633 million). Those losses arose principally from the provisions made to state the value of the Company's Interest Rate Swaps.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (*continued*)

9 Investment properties

	18 April 2017 £000
Valuation as at 15 April 2016	32,982
Revaluation	(647)
Value at 18 April 2017	32,335

The 2017 and 2016 valuations were made by Cushman & Wakefield (formerly DTZ Debenham Tie Leung - "DTZ") and Colliers International Healthcare UK LLP as independent external valuers, and has been prepared as at 18 April 2018, in accordance with the Appraisal Valuation Standards of the Royal Institution of Chartered Surveyors ("RICS"), on the basis of fair value. Properties have been valued on an individual basis. This has been incorporated into the financial statements.

10 Debtors: due within one year

	18 April 2017 £000	15 April 2016 £000
Deferred rent due from Tenant	537	537
Amounts owed from other Theatre Propcos	2,889	2,459
Less Provision	(2,889)	(2,459)
Prepayments and accrued income	3	3
	540	540

Deferred rent

The deferred rent receivable by the Company from the Tenant under the terms of the Deferred Rent Agreement has been shown as falling due within one year; being the earliest that the amount could be recovered under the terms of the Deferred Rent Agreement. The Director has considered the recoverability of the amount due, alongside amounts due under the Deferred Rent Agreement to other Theatre Propcos. Based upon publicly available information concerning the financial circumstances of the Tenant, the Director has concluded that there is a reasonable prospect that the amount is recoverable.

Amounts due from other Theatre Propcos

These amounts arose from payments made by the Company on behalf of other Theatre Propcos to repay and/or service the Theatre Propcos' Debt allocated to those companies, where their own rental income is insufficient to cover their obligations. These loans are deemed to be interest free and repayable on demand.

The Director has made full provision against the total amount receivable from the other Theatre Propcos.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (*continued*)

11 Debtors: due more than one year

	18 April 2017 £000	15 April 2016 £000
Financial assets - RPI swaps (Note 17)	1,050	598
	<u>1,050</u>	<u>598</u>

12 Creditors: due within one year

	18 April 2017 £000	15 April 2016 £000
Bank loans (note 14)	265	134
Other creditors	3	3
Accruals and deferred income	771	777
Financial liabilities - Interest rate swaps (note 17)	938	747
	<u>1,977</u>	<u>1,661</u>

Accruals

Accruals represent costs incurred not invoiced, and deferred income represents rent received in advance.

13 Creditors: due more than one year

	18 April 2017 £000	15 April 2016 £000
Bank loans (Note 14)	31,901	31,919
Capitalised loan arrangement fee	(75)	(112)
Financial liabilities - Interest rate swaps (note 17)	2,328	3,155
	<u>34,154</u>	<u>34,962</u>

14 Loan schedule

	18 April 2017 £000	15 April 2016 £000
Loan maturity analysis		
Due within one year	265	134
Due greater than one year, less than 5 years	31,901	31,919
Total loans due	<u>32,166</u>	<u>32,053</u>

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements
for the period ended 18 April 2017 (continued)

14 Loan schedule (continued)

The principal terms of the secured bank loan are set out below:

	Interest rate* %	2017 £000	Interest rate* %	2016 £000
Repayable in quarterly instalments with a lump sum payment on 15 April 2019	2.41% - 6.11%	16,578	2.63% - 6.33%	17,158
Repayable in a lump sum on 15 April 2019	0% - 7.25%	15,588	0% - 7.25%	14,895
Total due		<u>32,166</u>		<u>32,053</u>

*Where not fixed, the interest rate disclosed is the floating rate at period end, excluding the effect of the Interest Rate Swaps.

Security

The loan to the Company is secured by means of fixed and floating charges over all the of the Company's assets.

Similar security is provided by each Theatre Propco in respect of the Theatre Propcos' Debt and the loan amounts allocated to each Theatre Propco are cross-collateralised. The Company is therefore a guarantor of the total Theatre Propcos' Debt. At 18 April 2017, the total Theatre Propcos' Debt outstanding was £1,933.4 million (2016: £1,931.5 million).

15 Provision

	18 April 2017 £000	15 April 2016 £000
Deferred taxation	3,195	3,275
	<u>3,195</u>	<u>3,275</u>

16 Deferred taxation

	Tax on property gains 18.04.17 £'000	Tax losses available 18.04.17 £'000	Total 18.04.17 £'000
Opening deferred tax liability / (asset)	4,402	(1,127)	3,275
Adjustment for the change in rate by 1%	(220)	57	(163)
Adjustment of carried forward losses	-	(18)	(18)
Movement in property valuation	(195)	-	(195)
Tax loss recognised during the period (19%)	-	296	296
Closing deferred tax liability / (asset)	<u>3,987</u>	<u>(792)</u>	<u>3,195</u>

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (*continued*)

16 Deferred taxation (*continued*)

As set out in Note 8 to the financial statements, the Company has tax losses of £4.165 million (2016: £5.633 million) available to be used against taxable profits in future periods.

The recognition of the deferred tax asset in relation to those tax losses is determined by United Kingdom Generally Accepted Accounting Practice, with which the Company's accounting policies conform. This requires that a deferred tax asset is recognised only to the extent that it is probable that it will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

As at 18 April 2017, the Director concluded that the Company's tax losses will be recovered in full against the potential gain on sale of the investment properties, and/or future taxable profits, based on tax legislation in force at the date until the financial statements were approved. Following the reporting date, the UK Government has announced its intention to introduce retrospective legislation that will materially impact on the Company's ability to utilise its deferred tax losses carried forward. At the time of signing of these financial statements no date had been set for the introduction of this legislation and therefore no assessment of the impact can be made.

17 Financial instruments

The Company's financial instruments may be analysed as follows:

	18 April 2017 £000	15 April 2016 £000
Financial assets held at amortised cost	537	537
Financial assets held at fair value	1,050	598
Financial liabilities held at amortised cost	32,190	31,944
Financial liabilities held at fair value	3,266	3,902

Financial assets are measured at amortised cost and comprises of the deferred rent due from the tenant and accrued income.

Financial liabilities are measured at amortised cost credit risk and comprise of loans, trade creditors, other creditors and amounts due from group companies.

Financial assets at fair value

On 29 May 2015, Retail Price index ("RPI") swap contracts originally entered into by the Company's former immediate parent company were novated to the Company. The contractual counterparty holds "mirror image" RPI swap contracts with the Company's tenant. The two sets of contracts result in the annual rent increases payable by the tenant being fixed at 2.5%. The movement in the fair value of the RPI swap asset during the period reflects changes in anticipated inflation as measured by the RPI. The Directors have received a valuation from an appropriately skilled independent valuer for the RPI swaps that reflects both the terms of the RPI agreement as well as the credit risk of the Tenant.

	18 April 2017 £000	15 April 2016 £000
Opening fair value RPI swap asset	(598)	-
Novation of RPI swap asset	-	(364)
RPI Swap interest received or accrued during the period	85	43
RPI Swap cost paid or accrued during the period	(4)	(3)
Credit to the profit and loss account	(533)	(274)
Closing fair value RPI asset	(1,050)	(598)

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (*continued*)

17 Financial instruments (*continued*)

Financial liabilities at fair value

The Company (and the rest of the Theatre Propcos) has secured bank loans which bear interest at fixed and floating rates of interest, some of which is paid in cash and some of which is accrued on a "payment in kind (PIK)" basis. The senior components of these debts are covered by Interest Rate Swaps which mature in 2021. The swaps are carried at fair value.

	18 April 2017 £000	15 April 2016 £000
Opening fair value interest rate swap liability	3,902	3,889
Swap cost paid or accrued during the period	(935)	(674)
Charge to the profit and loss account	299	687
Closing fair value interest rate swap liability	3,266	3,902

Interest Rate Swap contracts with a principal amount of £16.7 million (2016: £17.2 million) have floating interest receipts linked to the 3 month LIBOR rate and have fixed interest rate payments at an interest rate commencing at 4.84% and rising to 6.13% over the term of the swaps.

The Director has received from the counterparties a statement of the liability at 18 April 2017 of the Interest Rate Swaps. He has also received a valuation from an appropriately skilled independent valuer, which corroborates the value received from the counterparties.

The movement in the fair value of the Interest Rate Swap during the period reflects changes in anticipated future long term interest rates, the cost of replacing the Interest Rate Swaps, and the contracted amounts payable by the Company during the period for the difference between floating and fixed interest rates.

18 Called up share capital

	18 April 2017 £000	15 April 2016 £000
Allotted , called up and fully paid		
101 Ordinary shares of £1 each (2016: 101)	-	-

On 18 April 2006, the Company was incorporated with 101 £1 shares issued at par. All shares issued during the period were ordinary share capital carrying equal voting rights.

GHG 18 (Saxon Clinic) Limited

Notes forming part of the financial statements for the period ended 18 April 2017 (*continued*)

19 Reserves

Called up share capital represents the nominal value of issued shares.

Amounts within share premium included any premium received on the issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium. On 4 June 2015, a capital reduction was implemented by means of a court order, under which the share premium account was cancelled and credited to reserves, reducing the balance on the share premium account to £Nil.

The profit and loss account includes all current and prior period retained profit and losses.

On 29 May 2015, the Company's then immediate parent, Hospital Midco S.a.r.l, novated to the Company for the sum of £1 its interest in a RPI swap instrument. The fair value at that date, of £0.363 million has been recognised as a capital contribution in the prior year.

20 Transactions with related parties

The Company is a wholly owned subsidiary of Hospital Topco Limited and has taken advantage of the exemption in FRS 102 not to disclose transactions with Hospital Topco Limited or other wholly owned subsidiaries within the group.

On 29 May 2015, certain of the Company's lenders became the shareholders of Hospital Topco Limited, the Company's ultimate parent company. The amount of the Company's loan facility attributable to shareholders as at 18 April 2017 was £10.3 million (2016: £10.7 million) with interest charged during the period of £0.412 million (2016: £0.345 million).

21 Contingent liabilities

Security provided regarding the Theatre Propcos' Debt

The Company has charged all its assets to secure its liabilities to the Lenders and to Interest Rate Swap counterparties. The Company has cross-collateralised that security with loans and Interest Rate Swaps made at the same time under the same overall arrangements to other Theatre Propcos and is therefore a guarantor of all such arrangements. At 18 April 2017, the total amount owed to the Lenders by all members of the Theatre Propcos was £1,933.4 million (2016: £1,931.5 million) the mark-to-market value of the Interest Rate Swaps was £195.7 million (2016: £233.8 million) and the aggregate market value of the property assets provided as security was £1,599.8 million (2016: £1,671.4 million) book value.

Future Deferred Tax

Following the reporting date, the UK Government has announced its intention to introduce retrospective legislation that will materially impact on the Company's ability to utilise its deferred tax losses carried forward. At the time of signing of these financial statements no date had been set for the introduction of this legislation and therefore no assessment of the impact can be made.

22 Subsequent events

There were no material post statement of financial position events requiring disclosure identified between 18 April 2017 and the date the financial statements were signed.

23 Controlling party

The Company's immediate parent company is Hospital Midco S.a.r.l, a company incorporated in Luxembourg. The Directors are of the opinion that the Company has no controlling party.